17 results on '"Hayashi, T."'
Search Results
2. 423PEffectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis.
3. 63P Nrf2 expression in surgically resected lung adenocarcinomas: Its association with clinicopathologic features and driver oncogene alterations.
4. 454PThe PD-L1 expression in surgically resected lung adenocarcinoma: Its correlations with the prognosis, driver oncogene alterations and clinicopathological features.
5. 244PLipid cell change in urothelial carcinoma: Signs of tumor aggression and the worst prognosis among the variants.
6. 657PCan preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?
7. 74P Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas.
8. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.
9. 430PEmetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis.
10. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
11. 411PComparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour.
12. 69PIrinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer.
13. 412PComprehensive mRNA-based screen for tyrosine kinase fusions and a de novo alternative transcription initiation site in soft tissue sarcomas.
14. 1358PComprehensive analysis for immune profiles of tumor microenvironment in non-small cell lung cancers: Prognostic effect of immunomodulatory molecules.
15. 639PVolume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?
16. 114PComprehensive analysis for immune profiles of tumor microenvironment in lung adenocarcinomas: Prognostic effect of immunomodulatory molecules.
17. P2–003A CASE OF AN ESOPHAGEAL CANCER PATIENT SURVIVING FOR OVER 4 YEARS AFTER CHEMORADIOTHERAPY AND SUBSEQUENT CHEMOTHERAPY.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.